Procept's Path to Profitability: 56,000 U.S. BPH Procedures Could Turn PRCT Around

Management is emphasizing a cleaner ramp toward profitability

ProCEPT has outlined a 2026 U.S. procedure range that reaches 56,000 U.S. procedures, but the more important shift is financial. Management is directing attention toward positive adjusted EBITDA in the fourth quarter of 2026.

What the reset changed

The key change is not just volume, but the quality of that volume. In the first quarter, management said results reflected a reset centered on commercial discipline. ProCEPT eliminated end-of-quarter purchasing incentives, reported $83.1 million in revenue, and recorded approximately 12,200 U.S. procedures in the quarter. Handpiece sales were also about 95% of procedures, which suggests field inventory is normalizing rather than being artificially built up. For investors, that matters because cleaner demand should make the revenue base easier to model.

This is where the bull and bear cases diverge. Bulls see a healthier growth engine; bears see a commercial realignment that could delay both growth and margin improvement. That risk is real, but it also appears time-limited. If the next few quarters show procedure momentum continuing to build while the company remains on track for positive adjusted EBITDA in the fourth quarter of 2026, the softer top-line reset could look constructive in hindsight.

The 54,000-to-56,000 target is a timing test

The annual range matters because it turns ProCEPT's story into a simple pacing problem. With approximately 12,200 U.S. procedures in the first quarter of 2026 already recorded, a 54,000 to 56,000 U.S. procedures target means the remaining nine months have to deliver roughly 42,000 to 44,000 more procedures. That works out to about 14,000 to 14,700 procedures per quarter on average. In practical terms, the full-year target only holds if the second half pulls noticeably ahead of the first.

What the target requires in the second half

This does not look like a flat-through-the-year rollout. The first quarter already showed activity moving after the commercial reset, but it did not yet clear the pace needed to support the full-year target. From here, investors need evidence that activations, case mix, and repeat usage are building as the year progresses.

Why procedure volume matters financially

Volume matters because it is the clearest input into the company's profit path. ProCEPT still expects approximately 65% gross margin for 2026. If that holds as volume rises, each additional procedure contributes to operating leverage because fixed costs are already in place. For a business aiming at positive adjusted EBITDA in the fourth quarter of 2026, procedure growth is the most direct way to close the gap.

Why demand quality still matters

Volume also has to be clean volume. Management said handpiece sales were about 95% of procedures, reflecting normalizing field inventory levels, and earlier noted it had reduced field inventory levels. That matters because the platform monetizes best when procedures, handpiece sales, and consumable use stay tightly linked. If procedure growth shows up late, or handpiece capture drifts away from procedure activity, the profitability case weakens quickly.

Investor Day also mattered because it anchored the target to an existing demand base. Management described BPH as a large, underpenetrated opportunity, pointed to more than 125K patients treated to date, and framed Aquablation therapy as a complete solution. That does not guarantee execution, but it does make the roadmap look more credible than a standalone growth slogan.

Watch three signals from here: - Quarterly U.S. procedures trending toward or above the roughly 14,000-to-14,700 H2 pace. - Handpiece sales staying close to procedure counts, near that 95% level. - Gross margin holding near approximately 65% gross margin for 2026 as volume rises.

If those pieces line up, the market can start treating ProCEPT as a profitability story rather than only a long-term narrative.

The stock still reflects execution risk

At roughly $18.22 shares on 8/4/2026 and a $1.0 billion market cap, ProCEPT is still being valued like a company that has not fully proved the case. That skepticism is part of the opportunity. The weaker price history means investors are no longer paying up purely for future promise; they are demanding visible execution. From that starting point, upside can come from both better operating results and a less skeptical multiple if the business keeps building from a Q1 base of approximately 12,200 U.S. procedures and stays on course for positive adjusted EBITDA in the fourth quarter of 2026.

What the market is already pricing in

The skeptical view is not hard to understand. The commercial reset created friction, and near-term disruption remains the cleanest argument for waiting. Investors are also looking at a company with Op Inc LTM is -109 Mil and SBC/Rev LTM is 16%, which means improvement in demand does not automatically remove dilution risk as the business matures.

Why the lower bar matters

Still, the setup is more interesting when expectations are lower. ProCEPT also entered 2026 with Net Debt/Equity is -16%, giving management some room to fund the ramp without obvious balance-sheet stress. More important, the company is still guiding to approximately 65% gross margin for 2026. If that holds, procedure volume becomes one of the fastest ways to turn growth into operating leverage.

The next earnings report should clarify the path

The next real checkpoint comes at earnings later this summer. With shares at $18.22 and weak multi-year price returns still weighing on sentiment, investors do not need a heroic story. They need three numbers to line up:

• Whether U.S. procedures of approximately 12,200 in the first quarter of 2026 are giving way to a faster run rate.
• Whether U.S. handpieces sold as percent of U.S. procedures in the first quarter of 2026 was approximately 95% holds or improves.
• Whether approximately 65% gross margin for 2026 remains a reliable guide as volume rises.

The practical checklist

• Positive signal: A quarter that shows clear procedure acceleration from the Q1 base while handpiece capture remains near 95%.
• Why it is not automatic: Another steady-but-slow quarter may not be enough to change market thinking on its own.
• What would weaken the case: If the business falls short of the 54,000 to 56,000 U.S. procedures target, if handpiece capture drifts meaningfully from procedure activity, or if the path to positive adjusted EBITDA in the fourth quarter of 2026 slips, the setup weakens quickly.